dc.contributor.author | Ozdemir, Secil Kepil | |
dc.contributor.author | Erkekol, Ferda Oner | |
dc.contributor.author | Unal, Derya | |
dc.contributor.author | Buyukozturk, Suna | |
dc.contributor.author | Gelincik, Asli | |
dc.contributor.author | Dursun, Adile Berna | |
dc.contributor.author | Karakaya, Gul | |
dc.contributor.author | Bavbek, Sevim | |
dc.date.accessioned | 2019-12-10T10:54:43Z | |
dc.date.available | 2019-12-10T10:54:43Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1018-2438 | |
dc.identifier.uri | https://doi.org/10.1159/000450952 | |
dc.identifier.uri | http://hdl.handle.net/11655/14684 | |
dc.description.abstract | Background: We previously reported perfect specificity and low sensitivity of skin tests in proton pump inhibitor (PPI)-induced immediate hypersensitivity reactions in a prospective multicenter study. Here, in a retrospective study, we aimed to further evaluate the diagnostic workup procedures and characteristics of the patients with suspected PPI hypersensitivity. Methods: This national multicenter study was conducted as a retrospective chart review of patients with a history of PPI-induced immediate hypersensitivity reaction. A total of 60 patients were included. Results of diagnostic workup procedures (standardized skin-prick, intradermal, and oral-provocation tests with PPIs) and the characteristics of the patients were analyzed. Results: Lansopra-zole was the most commonly suspected drug with 41 patients (68.3%), followed by pantoprazole in 12 patients (20.0%), esomeprazole in 6 (10.0%), rabeprazole in 4 (6.7%), and omeprazole in 1 (1.7%). Anaphylaxis (40 patients, 66.7%) was the most common clinical presentation followed by urticaria (17 patients, 28.3%). Diagnostic skin tests with the culprit PPI were positive in 13/26 patients (50.0%). Diagnostic oral-provocation tests were negative in 6/8 patients; 5 of these 6 patients had skin test results with the culprit PPI, and all were negative. Ten patients had at least 1 cross-reactivity. Extensive cross-reactivity (between > 2 PPIs) was detected in 4 patients. Conclusions: Lansoprazole was the most frequently implicated drug and anaphylaxis was the most frequent manifestation of PPI-induced hypersensitivity reactions. Physicians should be aware of the possible crossreactivity among PPIs; however, a safe, alternative PPI can usually be detected by a thorough drug allergy workup. (C) 2016 S. Karger AG, Basel | |
dc.language.iso | en | |
dc.publisher | Karger | |
dc.relation.isversionof | 10.1159/000450952 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Allergy | |
dc.subject | Immunology | |
dc.title | Management of Hypersensitivity Reactions to Proton Pump Inhibitors: A Retrospective Experience | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | International Archives Of Allergy And Immunology | |
dc.contributor.department | Göğüs Hastalıkları | |
dc.identifier.volume | 171 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 54 | |
dc.identifier.endpage | 60 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |